ProfileGDS4814 / ILMN_1830929
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 17% 2% 1% 11% 9% 19% 43% 10% 23% 14% 9% 2% 14% 3% 2% 3% 12% 2% 17% 19% 14% 14% 2% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)42.997117
GSM780708Untreated after 4 days (C2_1)37.25432
GSM780709Untreated after 4 days (C3_1)36.18061
GSM780719Untreated after 4 days (C1_2)41.565511
GSM780720Untreated after 4 days (C2_2)40.95479
GSM780721Untreated after 4 days (C3_2)43.315319
GSM780710Trastuzumab treated after 4 days (T1_1)48.412443
GSM780711Trastuzumab treated after 4 days (T2_1)41.118110
GSM780712Trastuzumab treated after 4 days (T3_1)44.21223
GSM780722Trastuzumab treated after 4 days (T1_2)42.251414
GSM780723Trastuzumab treated after 4 days (T2_2)40.75499
GSM780724Trastuzumab treated after 4 days (T3_2)37.52842
GSM780713Pertuzumab treated after 4 days (P1_1)42.182614
GSM780714Pertuzumab treated after 4 days (P2_1)38.18363
GSM780715Pertuzumab treated after 4 days (P3_1)37.51222
GSM780725Pertuzumab treated after 4 days (P1_2)38.61893
GSM780726Pertuzumab treated after 4 days (P2_2)41.775212
GSM780727Pertuzumab treated after 4 days (P3_2)37.69262
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)42.934517
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)43.408619
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)42.149314
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)42.257614
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)37.76032